Journal of the National Comprehensive Cancer Network : JNCCN
-
J Natl Compr Canc Netw · May 2019
LetterMutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma.
According to Dr. Anthony J. Olszanski, the most significant updates to the treatment of cutaneous melanoma include the recently published results of MSLT-II, which demonstrated that ultrasound-guided follow-up can be performed rather than a complete lymph node dissection, improving morbidity in patients with sentinel node metastases while not adversely affecting survival. In the adjuvant setting, the PD-1 inhibitors nivolumab and pembrolizumab are now FDA-approved, in addition to dabrafenib and trametinib, for patients with BRAF mutations.